Dwight Antony Hamilton, MD | |
2530 S Telshor Blvd, Suite 207, Las Cruces, NM 88011-4951 | |
(575) 522-6806 | |
(575) 521-8033 |
Full Name | Dwight Antony Hamilton |
---|---|
Gender | Male |
Speciality | Thoracic Surgery (cardiothoracic Vascular Surgery) |
Location | 2530 S Telshor Blvd, Las Cruces, New Mexico |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679560163 | NPI | - | NPPES |
P00875672 | Other | NM | RR MEDICARE |
73258547 | Medicaid | NM |
Mailing Address | Practice Location Address |
---|---|
Dwight Antony Hamilton, MD Po Box 6310, Las Cruces, NM 88006-6310 Ph: (575) 556-6400 | Dwight Antony Hamilton, MD 2530 S Telshor Blvd, Suite 207, Las Cruces, NM 88011-4951 Ph: (575) 522-6806 |
News Archive
A big question on people's minds these days: how long does immunity to SARS-CoV-2 last following infection?
Sodium fluoride supplements "have not been found by FDA to be safe or effective," according to the U.S. National Library of Medicine's website, reports the New York State Coalition Opposed to Fluoridation, Inc..
In an elaborate study, biologists of the University of Luxembourg have found out that small molecules named microRNAs are, against many hopes, not yet suitable for early diagnosis of skin cancer, as well as supposedly for other types of cancer, in blood samples. For the first time they analysed all microRNAs in the serum of healthy people and thus provided a first complete image of the human "miRNome" in blood samples, in reference to the better-known "genome".
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRimaâ„¢.
› Verified 8 days ago